ArticleTargeted oncology2017

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.

Michael Michael et al.PubMed ↗Publisher ↗

No numbers read from the abstract.